See the DrugPatentWatch profile for rivaroxaban

The patent for rivaroxaban, a blood thinner marketed under the brand name Xarelto, is set to expire in the United States on April 27, 2021 [1]. This information is based on the drug's listing in the Food and Drug Administration's (FDA) Orange Book [1]. However, it is important to note that the expiration of a patent does not necessarily mean that generic versions of the drug will become available immediately. Other factors, such as regulatory approval and legal challenges, can impact the availability of generic drugs.

It is also worth noting that the expiration date of the patent for rivaroxaban may vary in other countries. For example, according to DrugPatentWatch.com, the patent for rivaroxaban in Canada is set to expire on April 27, 2021 [2]. However, in the European Union, the patent for rivaroxaban expired in 2018 [3].

In summary, the patent for rivaroxaban in the United States is set to expire on April 27, 2021, but the availability of generic versions of the drug may be impacted by regulatory approval and legal challenges. The expiration date of the patent for rivaroxaban may vary in other countries.

Sources:

* [1] "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations." U.S. Food and Drug Administration. <https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations>
* [2] "Rivaroxaban (Xarelto) Patent Expiration & Generic Entry." DrugPatentWatch.com. <https://www.drugpatentwatch.com/rivaroxaban-xarelto-patent-expiration-generic-entry/>
* [3] "Rivaroxaban." European Medicines Agency. <https://www.ema.europa.eu/en/medicines/human/EPAR/xarelto>